{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 50,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_takeaways",
  "function": "cite_precedent",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The Venn diagram shows the intersection of genetic targets (TL1A, IL-23, a4b7). The bar chart compares 'All-comers' vs 'CDx+' (companion diagnostic positive) patient groups for two drugs (PRA023 and RVT-3101).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/11",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "chart",
      "text": "CLINICAL PRECEDENT TL1A studies UC clinical remission at 12 weeks",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c833a73-5f43-4e7c-a3d8-502f3aa833b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Genetic companion diagnostic (CDx) leveraging large-scale human genomic datasets",
      "attrs": null,
      "subkind": "venn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6309b4b-fd0e-4bd8-883f-50292c9cc089",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.68,
        "y": 0.45
      },
      "kind": "metric",
      "text": "25% 38% 20% 27%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8000c3a0-ae45-470a-9ef0-f4d471d546d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Spyre leverages genetically-driven patient selection to match disease drivers with therapeutic targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5678a03-e694-4ecb-b7f0-7b9bca46a364",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "d2a7648e-ae3a-45d8-b67d-babcd3dd2c28",
      "evidence": "Uses clinical precedent data to validate the efficacy of the proposed genetic selection strategy.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 9,
      "beatId": "7c8ec290-25a9-4de4-a40c-92ef8949c4a2",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0317e287-091e-44c2-9f1e-4137f5bb7b9e",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline, answering the question of how to address unmet needs in IBD.",
      "position": 0,
      "objective": "What problem does Spyre aim to solve and how?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}